Purple Biotech reported shrinking losses and successful trials, but faces uncertainty and decreased stock value.

From StockTwits: 2025-03-11 00:36:16

Purple Biotech reported having $8.2 million in cash as of Dec. 31, 2024, enough to fund operations until mid-2026. The company’s shares closed down 3.4% after disappointing financial results, with a net loss of $0.4 million in Q4 2024. CEO Gil Efron highlighted successful trials for cancer therapy candidates CM24 and NT219. Retail traders showed optimism, but questions remain about FDA approval strategy and the company’s capital-raising motives. Purple Biotech raised $2.8 million through a direct offering and $1.5 million via an open-market sale. The stock has dropped over 45% this year.



Read more at StockTwits: Purple Biotech’s Shrinking Losses Keep Retail Sentiment In The Green, But Other Pressures Loom